Antidepressants: Signal Transduction and Gene Expression
Antidepressants: Signal Transduction and Gene Expression
批准号:
7433895
负责人:
RONALD S. DUMAN
金额:
$34.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-09-01 至 2010-05-31
关键词:
AcuteAmygdaloid structureAntidepressive AgentsBehaviorBehavioral ModelBrain-Derived Neurotrophic FactorChronicClassCorpus striatum structureCustomCyclic AMPCyclic AMP-Responsive DNA-Binding ProteinDevelopmentDiseaseDominant-Negative MutationDrug Delivery SystemsEngineeringGene ExpressionGenesHippocampus (Brain)HumanKnockout MiceLaboratoriesLeadLearned HelplessnessMediatingMental DepressionMethodsMitogen-Activated Protein KinasesMolecularMutant Strains MiceNorepinephrinePDE4BPathway interactionsPharmaceutical PreparationsPharmacological TreatmentPhosphoric Monoester HydrolasesProtein phosphataseProteinsRecombinantsRegulationRodent ModelRoleSerotoninSignal PathwaySignal TransductionStandards of Weights and MeasuresStructureSwimmingTestingTherapeuticTransduction GeneViralViral VectorWeekWorkcDNA Arraysdepressive symptomsdrug developmentfeedinginhibitor/antagonistneurotrophic factornovelnull mutationphosphodiesterase IVphosphoric diester hydrolaseresponsereuptakesocioeconomicstheories
中文摘要
描述(申请人提供):抑郁症是一种破坏性的疾病,具有广泛的社会经济影响。尽管抑郁症的药物治疗已有40多年的历史,但这些药物并不总是有效的,它们需要数周甚至数月的治疗。大多数抗抑郁药的急性作用是通过抑制去甲肾上腺素(NE)和5-羟色胺(5-羟色胺)的再摄取或分解而发生的,但慢性抗抑郁药治疗(ADT)的治疗作用机制尚不清楚。对长期ADT的要求导致了一种假设,即细胞和分子对升高的NE和5-羟色胺水平的适应介导了治疗反应。我们实验室的研究表明,cAMP-CREB(cAMP-CREB)信号转导通路和该通路的靶点BDNF(脑源性神经营养因子)参与了ADT的作用。我们已经证明,不同种类的抗抑郁药,包括NE和5-羟色胺选择性再摄取抑制剂,可以增加边缘结构中CREB和BDNF的表达,并且CREB和BDNF足以在行为模型中产生ADT反应。这项工作导致了抑郁症的神经营养假说,这是该领域的领先理论,该建议的目的之一是通过确定CREB和BDNF是否必要以及ADT反应是否充分来检验这一假说。这些研究还表明,cAMP-CREB或BDNF信号的激活将产生ADT反应。研究表明,通过抑制cAMP磷酸二酯酶4型(PDE4)激活cAMP-CREB级联反应的药物在啮齿动物模型和人类中产生ADT反应,这一点得到了支持。这项建议的另一个主要目的是确定哪种PDE4亚型(S)是ADT反应的基础。一个相关的目的是确定BDNF信号通路的激活是否也产生ADT反应,并研究该通路中的蛋白质,特别是蛋白磷酸酶,可能成为药物开发的靶点。因为没有针对这些靶点的选择性药物,我们将使用互补的方法,包括我们已经设计或获得的零突变小鼠,以及局部表达野生型或显性负性基因的病毒载体。这些研究将进一步确定ADT作用的潜在机制,并为开发更快、更有效的药物确定新的药物靶点。
英文摘要
DESCRIPTION (provided by applicant): Major depressive illness is a devastating disorder with broad socioeconomic effects. Although pharmacological treatments for depression have been available for over 40 years, these drugs are not always effective and they require weeks or even months of treatment. The acute actions of most antidepressants occur via inhibition of the reuptake or breakdown of norepinephrine (NE) and serotonin (5-HT), but the mechanisms underlying the therapeutic actions of chronic antidepressant treatment (ADT) remain largely unknown. The requirement for long-term ADT has lead to the hypothesis that cellular and molecular adaptations to elevated levels of NE and 5-HT mediate the therapeutic response. Studies from our laboratory have demonstrated that the cAMP-CREB (cAMP response element binding protein) signal transduction cascade and a target of this pathway, BDNF (brain derived neurotrophic factor), contribute to the action of ADT. We have demonstrated that different classes of antidepressants, including NE and 5-HT selective reuptake inhibitors, increase CREB and BDNF expression in limbic structures, and that CREB and BDNF are sufficient to produce an ADT-response in behavioral models. This work has resulted in the neurotrophic hypothesis of depression, a leading theory in the field, and one of the aims of this proposal is to test this hypothesis by determining if CREB and BDNF are necessary, as well as sufficient for an ADT-response. These studies also indicate that activation of cAMP-CREB or BDNF signaling would produce an ADT response. This is supported by studies demonstrating that drugs that activate the cAMP-CREB cascade, by inhibition of the cAMP phosphodiesterase type 4 (PDE4), produces an ADT-response in rodent models and in humans. Another major aim of this proposal is to identify which of the PDE4 subtype(s) underlies the ADT response. A related aim is to determine if activation of the BDNF signaling pathway also produces an ADT response, and to investigate proteins in this pathway, particularly protein phosphatases, that could be targeted for drug development. Because there are no selective drugs for these targets, we will use complimentary approaches, including null mutant mice that we have engineered or obtained and viral vectors for local expression of wild type or dominant negative genes. These studies will further characterize the mechanisms underlying the action of ADT and identify novel drug targets for the development of faster acting and more efficacious medications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synaptic mechanisms underlying the rapid antidepressant actions of scopolamine
-
批准号:8934161
-
项目类别:
-
资助金额:$43.2万
-
财政年份:2014
-
负责人:RONALD S. DUMAN
-
依托单位:
Synaptic mechanisms underlying the rapid antidepressant actions of scopolamine
-
批准号:8810419
-
项目类别:
-
资助金额:$48.0万
-
财政年份:2014
-
负责人:RONALD S. DUMAN
-
依托单位:
Role of mTOR and Synaptogenesis in the Actions of Rapid-Acting Antidepressants
-
批准号:8738247
-
项目类别:
-
资助金额:$8.23万
-
财政年份:2013
-
负责人:RONALD S. DUMAN
-
依托单位:
Role of mTOR and Synaptogenesis in the Actions of Rapid-Acting Antidepressants
-
批准号:8812007
-
项目类别:
-
资助金额:$49.17万
-
财政年份:2011
-
负责人:RONALD S. DUMAN
-
依托单位:
Role of mTOR and synaptic protein synthesis in the rapid antidepressant actions o
-
批准号:8097791
-
项目类别:
-
资助金额:$49.17万
-
财政年份:2011
-
负责人:RONALD S. DUMAN
-
依托单位:
Role of mTOR and synaptic protein synthesis in the rapid antidepressant actions o
-
批准号:8230821
-
项目类别:
-
资助金额:$49.17万
-
财政年份:2011
-
负责人:RONALD S. DUMAN
-
依托单位:
Role of mTOR and Synaptogenesis in the Actions of Rapid-Acting Antidepressants
-
批准号:8434258
-
项目类别:
-
资助金额:$47.2万
-
财政年份:2011
-
负责人:RONALD S. DUMAN
-
依托单位:
Role of mTOR and Synaptogenesis in the Actions of Rapid-Acting Antidepressants
-
批准号:8635386
-
项目类别:
-
资助金额:$57.4万
-
财政年份:2011
-
负责人:RONALD S. DUMAN
-
依托单位:
The ability of the transcription factor CREB in the Nac to regulate mood
-
批准号:8114141
-
项目类别:
-
资助金额:$32.88万
-
财政年份:2010
-
负责人:RONALD S. DUMAN
-
依托单位:
The ability of the transcription factor CREB in the Nac to regulate mood
-
批准号:7664379
-
项目类别:
-
资助金额:$31.42万
-
财政年份:2008
-
负责人:RONALD S. DUMAN
-
依托单位:
The ability of the transcription factor CREB in the Nac to regulate mood
-
批准号:7333042
-
项目类别:
-
资助金额:$23.66万
-
财政年份:2007
-
负责人:RONALD S. DUMAN
-
依托单位:
Profiling Gene Expression in Major Depression
-
批准号:7492640
-
项目类别:
-
资助金额:$27.77万
-
财政年份:2005
-
负责人:RONALD S. DUMAN
-
依托单位:
Profiling Gene Expression in Major Depression
-
批准号:6944556
-
项目类别:
-
资助金额:$30.42万
-
财政年份:2005
-
负责人:RONALD S. DUMAN
-
依托单位:
Profiling Gene Expression in Major Depression
-
批准号:7283751
-
项目类别:
-
资助金额:$27.77万
-
财政年份:2005
-
负责人:RONALD S. DUMAN
-
依托单位:
Profiling Gene Expression in Major Depression
-
批准号:7126432
-
项目类别:
-
资助金额:$28.6万
-
财政年份:2005
-
负责人:RONALD S. DUMAN
-
依托单位:
Early environment and the neurobiology of depression
-
批准号:6752130
-
项目类别:
-
资助金额:$3.37万
-
财政年份:2003
-
负责人:RONALD S. DUMAN
-
依托单位:
Early environment and the neurobiology of depression
-
批准号:6901029
-
项目类别:
-
资助金额:$3.2万
-
财政年份:2003
-
负责人:RONALD S. DUMAN
-
依托单位:
Early environment and the neurobiology of depression
-
批准号:6630673
-
项目类别:
-
资助金额:$3.85万
-
财政年份:2003
-
负责人:RONALD S. DUMAN
-
依托单位:
Gene Expression Profile of Antidepressants
-
批准号:6534953
-
项目类别:
-
资助金额:$14.43万
-
财政年份:2002
-
负责人:RONALD S. DUMAN
-
依托单位:
REGULATION OF ADULT NEUROGENESIS--STRESS /ANTIDEPRESSANT
-
批准号:6614515
-
项目类别:
-
资助金额:$11.07万
-
财政年份:2002
-
负责人:RONALD S. DUMAN
-
依托单位: